StemInov – new member

12 March 2024
New member

StemInov is a biopharmaceutical company specializing in the development of “WhartSep”, an innovative mesenchymal stem cell therapy with immunomodulatory properties of particular interest in the treatment of septic shock. The aim of the project is to administer the newly-developed drug “WhartSep”, the proof-of-concept of which has been demonstrated in animals suffering from septic shock. This treatment responds to the need for intensive care through an innovative clinical development strategy and a new therapeutic concept. The company’s primary objective is to carry out clinical trials for this drug until the end of Phase II clinical trials, which corresponds to the demonstration of proof of concept in humans. To know more